3737 — Zhongzhi Pharmaceutical Holdings Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapContrarian

Market Cap
HK$1.05bn
Enterprise Value
HK$1.07bn
Revenue
CNY2.05bn

Annual income statement for Zhongzhi Pharmaceutical Holdings, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,342	1,604	1,747	1,826	2,050
Cost of Revenue
Gross Profit	835	991	1,064	1,075	1,218
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,182	1,431	1,678	1,689	1,834
Operating Profit	160	172	68.9	137	215
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	156	167	61.8	131	208
Provision for Income Taxes
Net Income After Taxes	115	139	52.4	107	164
Minority Interest
Net Income Before Extraordinary Items
Net Income	115	139	52.1	106	163
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	115	139	52.1	106	163
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.137	0.167	0.062	0.125	0.192
Dividends per Share
Special Dividends per Share